Cystic Fibrosis: A Review.
Ong T, Ramsey BW.
JAMA. 2023 Jun 6;329(21):1859-1871. doi: 10.1001/jama.2023.8120.
The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant.
Burgel PR, Sermet-Gaudelus I, Durieu I, Kanaan R, Macey J, Grenet D, Porzio M, Coolen-Allou N, Chiron R, Marguet C, Douvry B, Dufeu N, Danner-Boucher I, Foucaud P, Lemonnier L, Girodon E, Da Silva J, Martin C; French CF Reference Network study group; Andrejak C, Priou P, Richaud-Thiriez B, Macey J, Montcouquiol S, Douvry B, Remus N, Fanton A, Coolen-Allou N, Gachelin E, Vuillard C, Audousset C, Duthoit L, Bellet-Fraysse E, Languepin J, Durieu I, Nove-Josserand R, Ohlmann C, Raynaud Q, Dufeu N, Chiron R, Billon Y, Danner-Boucher I, Tissot A, Leroy S, Aubourg F, Burnet E, Burgel PR, Carlier N, Da Silva J, Fajac I, Girodon E, Kanaan R, Honoré I, Martin C, Le Bourgeois M, Sermet-Gaudelus I, Le Clainche-Viala L, Corvol H, Dehillotte C, Foucaud P, Lemonnier L, Brinchault G, Ravoninjatovo B, Le Bihan J, Ramel S, Marguet C, Porzio M, Weiss L, Grenet D, de Miranda S, Cosson L, Mankikian J, Pouradier D.
Eur Respir J. 2023 May 5;61(5):2202437. doi: 10.1183/13993003.02437-2022. Print 2023 May.
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.
Lopes-Pacheco M.
Front Pharmacol. 2020 Feb 21;10:1662. doi: 10.3389/fphar.2019.01662. eCollection 2019.
Pulmonary aspergillosis: a clinical review.
Kousha M, Tadi R, Soubani AO.
Eur Respir Rev. 2011 Sep 1;20(121):156-74. doi: 10.1183/09059180.00001011.
Clinical Manifestation and Treatment of Allergic Bronchopulmonary Aspergillosis.
Agarwal R, Muthu V, Sehgal IS.
Semin Respir Crit Care Med. 2024 Feb;45(1):114-127. doi: 10.1055/s-0043-1776912. Epub 2023 Dec 28.
CFTR Modulators: Current Status and Evolving Knowledge.
Regard L, Martin C, Da Silva J, Burgel PR.
Semin Respir Crit Care Med. 2023 Apr;44(2):186-195. doi: 10.1055/s-0042-1758851. Epub 2022 Dec 19.
A new era for people with cystic fibrosis.
Bierlaagh MC, Muilwijk D, Beekman JM, van der Ent CK.
Eur J Pediatr. 2021 Sep;180(9):2731-2739. doi: 10.1007/s00431-021-04168-y. Epub 2021 Jul 2.
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.
Bacalhau M, Camargo M, Magalhães-Ghiotto GAV, Drumond S, Castelletti CHM, Lopes-Pacheco M.
Pharmaceuticals (Basel). 2023 Mar 8;16(3):410. doi: 10.3390/ph16030410.
Hepatic Manifestations of Cystic Fibrosis.
Sakiani S, Kleiner DE, Heller T, Koh C.
Clin Liver Dis. 2019 May;23(2):263-277. doi: 10.1016/j.cld.2018.12.008. Epub 2019 Feb 21.
Nontuberculous Mycobacterial Infections in Cystic Fibrosis.
Martiniano SL, Nick JA, Daley CL.
Clin Chest Med. 2022 Dec;43(4):697-716. doi: 10.1016/j.ccm.2022.06.010.
